IDRI receives funding for its Tuberculosis Drug Accelerator program
Last year, IDRI received several million dollars for the program, which seeks to identify targets and leads that can be used in the development of a more effective TB vaccine. The additional money will be used to expand IDRI's current activities and push the pharmaceutical community to increase their support of TB drug discovery.
"These additional funds will greatly help our drug discovery efforts, enabling us to increase our interactions with the academic and pharmaceutical communities to find new treatments for tuberculosis," Dr. Stephen Reed, IDRI's president and founder, said.
The Seattle-based nonprofit intends to expand its early drug discovery capability by increasing its ability to screen for anti-tubercular compounds and its evaluation of those identified.
"We are very pleased and thankful to be able to expand our efforts in drug discovery enabling progress towards our goal of developing new antibiotics for tuberculosis," Professor Tanya Parish, the director of TB drug discovery at IDRI, said. "The additional funding will allow us to screen a wider variety of compounds and progress them into drug candidates more rapidly."